Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy

被引：2

作者：

Garcia, Cristina Cano ^{[1
,2
,18
]}

Flammia, Rocco S. ^{[3
]}

Piccinelli, Mattia ^{[1
,4
]}

Panunzio, Andrea ^{[1
,5
]}

Tappero, Stefano ^{[1
,6
,7
]}

Barletta, Francesco ^{[1
,8
]}

Incesu, Reha-Baris ^{[1
,9
]}

Law, Kyle W. ^{[1
]}

Morra, Simone ^{[1
,10
]}

Tian, Zhe ^{[1
]}

Saad, Fred ^{[1
]}

Kapoor, Anil ^{[11
]}

Shariat, Shahrokh F. ^{[12
,13
,14
,15
]}

Longo, Nicola ^{[10
]}

Tilki, Derya ^{[16
,17
]}

Briganti, Alberto ^{[8
]}

Terrone, Carlo ^{[6
,7
]}

Antonelli, Alessandro ^{[5
]}

De Cobelli, Ottavio ^{[4
]}

Hoeh, Benedikt ^{[2
]}

Kluth, Luis A. ^{[2
]}

Chun, Felix K. H. ^{[2
]}

Karakiewicz, Pierre I. ^{[1
]}

机构：

[1] Univ Montreal, Div Urol, Canc Prognost & Hlth Outcomes Unit, Hlth Ctr, Montreal, PQ, Canada

[2] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany

[3] Sapienza Rome Univ, Policlin Umberto Hosp 1, Dept Maternal Child & Urol Sci, Rome, Italy

[4] IRCCS, IEO European Inst Oncol, Dept Urol, Milan, Italy

[5] Univ Verona, Dept Urol, Azienda Osped Univ Integrata Verona, Verona, Italy

[6] IRCCS Policlin San Martino, Dept Urol, Genoa, Italy

[7] Univ Genoa, Dept Surg & Diagnost Integrated Sci DISC, Genoa, Italy

[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Div Oncol, Unit Urol,Gianfranco Soldera Prostate Canc Lab, Milan, Italy

[9] Univ Hosp Hamburg Eppendorf, Prostate Canc Ctr, Martini Klin, Hamburg, Germany

[10] Univ Naples Federico II, Dept Neurosci Reprod Sci & Odontostomatol, Urol Unit, Naples, Italy

[11] McMaster Univ, McMaster Inst Urol, Div Urol, Hamilton, ON, Canada

[12] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria

[13] Weill Cornell Med Coll, Dept Urol, New York, NY USA

[14] Univ Texas Southwestern, Dept Urol, Dallas, TX USA

[15] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Dept Urol, Amman, Jordan

[16] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany

[17] Koc Univ Hosp, Dept Urol, Istanbul, Turkiye

[18] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Urol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany

来源：

CLINICAL GENITOURINARY CANCER | 2024年 / 22卷 / 01期

关键词：

Clear cell; Metastatic renal cell carcinoma; Partial nephrectomy; SEER; Other-cause mortality; OPEN-LABEL; EVEROLIMUS;

D O I：

10.1016/j.clgc.2023.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We tested within a large population-based and matched analyses if previously described advantages in othercause mortality (OCM) for clear cell metastatic renal cell carcinoma (ccmRCC) patients undergoing partial cytoreductive nephrectomy (PCN) still apply, relative to radical cytoreductive nephrectomy (RCN). We confirm the existence of OCM advantage after PCN vs. RCN in contemporary ccmRCC patients and PCN may continue being considered as a valuable alternative to RCN, when technically feasible. Background: It is unknown whether previously reported other-cause mortality (OCM) advantage of partial cytoreductive nephrectomy (PCN) vs. radical cytoreductive nephrectomy (RCN) still applies to contemporary clear cell metastatic renal cell carcinoma (ccmRCC) patients. Materials and Methods: We relied on the Surveillance, Epidemiology and End Results (SEER) database (2004-2019) to identify ccmRCC patients treated with PCN and RCN. Temporal trends of PCN rates within the SEER database were tabulated. After propensity score matching (PSM), cumulative incidence plots depicted 5-year OCM and cancer-specific mortality (CSM) of PCN and RCN patients. Multivariable Cox regression models tested for differences between PCN vs. RCN. Results: Of 5149 study patients, 237 (5%) underwent PCN vs. 4912 (95%) RCN. In the SEER database 2004 to 2019, rates of PCN in ccmRCC patients increased from 3.0% to 8.0% (estimated annual percent change [EAPC]: 3.0%; P = .04). After PSM, 5-year OCM rates were 2.4 vs. 7.5% for respectively PCN vs. RCN patients (P = .036). 5-year CSM rates were 50.8 vs. 53.6% for respectively PCN and RCN patients (P = .57). In multivariable Cox regression models, PCN was associated with lower OCM (Hazard Ratio (HR): 0.39; 95% confidence interval (CI): 0.18-0.84; P = .02) but did not affect CSM rates (HR: 0.99; 95% CI: 0.76-1.29; P = .96). Conclusions: We confirm the existence of OCM advantage after PCN vs. RCN in contemporary ccmRCC patients.

引用

页码：1 / 6

页数：6

共 50 条

[1] Differences in survival of clear cell metastatic renal cell carcinoma patients according to partial vs. radical nephrectomy
Garcia, Cano C.
Flammia, R. S.
Piccinelli, M.
Panunzio, A.
Tappero, S.
Barletta, F.
Incesu, R-B
Law, K.
Tian, Z.
Saad, F.
Kapoor, A.
Shariat, S. F.
Tilki, D.
Briganti, A.
Terrone, C.
Antonelli, A.
De Cobelli, O.
Hoeh, B.
Kluth, L. A.
Chun, F. K. H.
Karakiewicz, P., I
[J]. EUROPEAN UROLOGY, 2023, 83 : S477 - S478
[2] Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy
Siech, C.
Incesu, R. B.
Morra, S.
Scheipner, L.
Baudo, A.
Jannello, L. M. I.
de Angelis, M.
Goyal, J. A.
Tian, Z.
Saad, F.
Shariat, S. F.
Tilki, D.
Longo, N.
Carmignani, L.
De Cobelli, O.
Ahyai, S.
Briganti, A.
Mandel, P.
Kluth, L. A.
Chun, F. K. H.
Karakiewicz, P. I.
[J]. EUROPEAN UROLOGY, 2024, 85 : S1863 - S1863
[3] SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY VS. NO SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Zini, Laurent
Capitanio, Umberto
Perrotte, Paul
Jeldres, Claudio
Shariat, Shahrokh F.
Arjane, Philippe
Widmer, Hugues
Briganti, Alberto
Gallina, Andrea
Suardi, Nazareno
Patard, Jean-Jacques
Karakiewicz, Pierre I.
[J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 497 - 497
[4] SURVIVAL AFTER CYTOREDUCTIVE NEPHRECTOMY VS. NO SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Zini, L.
Capitanio, U.
Perrotte, P., I
Jeldres, C.
Isbarn, H.
Shariat, S. F.
Arjane, P., I
Widmer, H.
Briganti, A.
Gallina, A.
Suardi, N.
Patard, J.
Montorsi, F.
Karakiewicz, P., I
[J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 180 - 180
[5] Cytoreductive nephrectomy in primary metastatic clear cell renal cell carcinoma
Beisland, Christian
[J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2020, 54 (06) : 500 - 500
[6] Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Chakiryan, Nicholas H.
Gore, L. Robert
Reich, Richard R.
Dunn, Rodney L.
Jiang, Da David
Gillis, Kyle A.
Green, Elizabeth
Hajiran, Ali
Hugar, Lee
Zemp, Logan
Zhang, Jingsong
Jain, Rohit K.
Chahoud, Jad
Spiess, Philippe E.
Manley, Brandon J.
Sexton, Wade J.
Hollenbeck, Brent K.
Gilbert, Scott M.
[J]. JAMA NETWORK OPEN, 2022, 5 (05)
[7] Partial cytoreductive nephrectomy versus cytoreductive nephrectomy in metastatic renal cell carcinoma.
Vitruk, Iurly
Stakhovskyi, Oleksandr
Voylenko, Oleg
Kotov, Volodymyr
Pikul, Maxim
Stakhovsky, Eduard
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma
Palumbo, Carlotta
Mistretta, Francesco A.
Knipper, Sophie
Pecoraro, Angela
Tian, Zhe
Dzyuba-Negrean, Cristina
Shariat, Shahrokh F.
Saad, Fred
Simeone, Claudio
Berruti, Alfredo
Briganti, Alberto
Kapoor, Anil
Antonelli, Alessandro
Karakiewicz, Pierre I.
[J]. CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : E730 - E738
[9] Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis
Xiao, Wen-Jun
Zhu, Yao
Dai, Bo
Zhang, Hai-Liang
Ye, Ding-Wei
[J]. INTERNATIONAL BRAZ J UROL, 2015, 41 (02): : 288 - 295
[10] Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma
Shen, X. -P.
Xie, M.
Wang, J. -S.
Guo, X.
[J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5684 - 5691

← 1 2 3 4 5 →